Targeting mRNA translation in Parkinson's disease.

08:00 EDT 8th April 2019 | BioPortfolio

Summary of "Targeting mRNA translation in Parkinson's disease."

Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The exact cause(s) of PD is not well understood, although genetic mutations are associated with some forms of the disease. Many of these mutations, in particular those that are found in LRRK2, DJ1, PINK1, and Parkin, are linked to the deregulation of mRNA translation, suggesting that this process is important for the onset of PD. Herein, we highlight recent studies that provide insights into the molecular mechanisms that relate mRNA translation to PD. These studies confirm the central role of translation in PD, emphasising the potential of restoring mRNA translation functionality as a new therapeutic treatment against PD, and providing novel targets for developing new chemical agents to target this disease.


Journal Details

This article was published in the following journal.

Name: Drug discovery today
ISSN: 1878-5832


DeepDyve research library

PubMed Articles [21568 Associated PubMed Articles listed on BioPortfolio]

Alternative mechanisms of translation initiation: An emerging dynamic regulator of the proteome in health and disease.

Eukaryotic mRNAs were historically thought to rely exclusively on recognition and binding of their 5' cap by initiation factors to effect protein translation. While internal ribosome entry sites (IRES...

Mobilizing Parkinson's Disease: The Future of Exercise.

Exercise is increasingly recognized as an important element in the treatment of Parkinson's disease but what is exercise targeting? What accounts for the benefits observed in Parkinson's disease? Is e...

Tracking of single tRNAs for translation kinetics measurements in chloramphenicol treated bacteria.

Chloramphenicol is a broad-spectrum antibiotic targeting the protein synthesis machinery by binding to the bacterial ribosome. Chloramphenicol has been considered a classic general inhibitor of transl...

A Parkinson's Disease Patient without Corpus Callosum.

The authors report of a patient with Parkinson's disease in whom imaging revealed a complete agenesis of the corpus callosum. Although this co-occurrence is probably coincidental, this finding suggest...

The Effect of 20 Hz versus 1 Hz Repetitive Transcranial Magnetic Stimulation on Motor Dysfunction in Parkinson's Disease: Which Is More Beneficial?

There is evidence that both high and low frequency rTMS may have therapeutic effects on motor performance of Parkinson's disease.

Clinical Trials [5243 Associated Clinical Trials listed on BioPortfolio]

Italian Validation of the Revised MDS-Unified Parkinson's Disease Rating Scale

The present study is part of an international program and deals with the translation and validation program for the Italian version of the MDS-UPDRS. The program will be articulated in th...

Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease

The purpose of this study is to evaluate the microbiome of medicated and non-medicated subjects diagnosed with Parkinson's disease. Where available, in comparison to the microbiome of a he...

Special Survey on PD Patients With Renal Dysfunction

The survey is conducted to collect safety and effectiveness information targeting patients who have both Parkinson's disease and renal dysfunction treated with Pramipexole in the daily cli...

Adaptation Process of Patient-Reported Outcomes, an eVALuation Study

Objectives: To identify the respective contributions of back-translations and of the expert committee in the process of cultural adaptation of patient reported outcome with an experimental...

Comparison of Two Rehabilitation Programs in Patients With Mild to Moderate Parkinson's Disease.

Parkinson's disease is a major source of handicap, for which physical treatments are often underutilized with respect to chemical or surgical treatments. Yet, dopaminergic treatments alone...

Medical and Biotech [MESH] Definitions

The small RNA molecules, 73-80 nucleotides long, that function during translation (TRANSLATION, GENETIC) to align AMINO ACIDS at the RIBOSOMES in a sequence determined by the mRNA (RNA, MESSENGER). There are about 30 different transfer RNAs. Each recognizes a specific CODON set on the mRNA through its own ANTICODON and as aminoacyl tRNAs (RNA, TRANSFER, AMINO ACYL), each carries a specific amino acid to the ribosome to add to the elongating peptide chains.

A heterogeneous-nuclear ribonucleoprotein found in the CELL NUCLEUS and the CYTOPLASM. Heterogeneous-nuclear ribonucleoprotein K has been implicated in the regulation of gene expression at nearly all levels: GENETIC TRANSCRIPTION; mRNA processing (RNA PROCESSING, POST-TRANSCRIPTIONAL), mRNA transport, mRNA stability, and translation (TRANSLATION, GENETIC). The hnRNP protein has a strong affinity for polypyrimidine-rich RNA and for single-stranded polypyrimidine-rich DNA. Multiple hnRNP K protein isoforms exist due to alternative splicing and display different nucleic-acid-binding properties.

Proteins associated with sporadic or familial cases of PARKINSON DISEASE.

An RNA-binding protein characterized by three RNA RECOGNITION MOTIFS. It binds to AU RICH ELEMENTS in the 3'-untranslated regions of mRNA and regulates alternative pre-RNA splicing and mRNA translation; it may also function in APOPTOSIS. Mutations in the TIA-1 gene are associated with WELANDER DISTAL MYOPATHY.

Proteins that bind to the 3' polyadenylated region of MRNA. When complexed with RNA the proteins serve an array of functions such as stabilizing the 3' end of RNA, promoting poly(A) synthesis and stimulating mRNA translation.

Quick Search


DeepDyve research library

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Searches Linking to this Article